Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Harvard Business School
Boehringer Ingelheim
Deloitte
Fuji
Teva
Medtronic
Queensland Health
Express Scripts
Accenture

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,753,265

« Back to Dashboard

Summary for Patent: 5,753,265

Title: Multiple unit pharmaceutical preparation
Abstract:A new pharmaceutical multiple unit tableted dosage form containing as active ingredient an acid labile H.sup.+ K.sup.+ -ATPase inhibitor or an alkaline salt thereof or one of its single enantiomers or an alkaline salt thereof, a method for the manufacture of such a formulation, and the method of treatment with such a formulation in medicine.
Inventor(s): Bergstrand; Pontus John Arvid (Gothenburg, SE), Lovgren; Kurt Ingmar (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/464,774
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Compound; Process; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,753,265

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9402431-2Jul 08, 1994
PCT Information
PCT FiledJune 07, 1995PCT Application Number:PCT/SE95/00678
PCT Publication Date:January 25, 1996PCT Publication Number: WO96/01624

International Patent Family for Patent: 5,753,265

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1152671► Subscribe
Czech Republic9600730► Subscribe
Czech Republic294380► Subscribe
Czech Republic9600731► Subscribe
Germany69533470► Subscribe
Denmark0723437► Subscribe
Estonia03280► Subscribe
Estonia03292► Subscribe
European Patent Office0723434► Subscribe
European Patent Office0723437► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Farmers Insurance
Covington
UBS
Federal Trade Commission
Julphar
Medtronic
Chinese Patent Office
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot